Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.44 |
| ▸ | MAT2A | P31153 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065169 | 0.83 | MAPK14 (0.36) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1065129 | 0.81 | MAPK14 (0.43) | MAPK14MAT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL1061199 | 0.81 | MAT2A (0.44) | MAPK14MAT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL1062919 | 0.79 | MAPK14 (0.42) | MAPK14L3MBTL1MAPK13MAPK12MAPK11 | |
| SCHEMBL5255371 | 0.78 | MAPK14 (0.44) | MAPK14L3MBTL1MAPK13MAPK12MAPK11 | |
| SCHEMBL4174284 | 0.76 | MAPK14 (0.48) | MAPK14L3MBTL1MAPK13MAPK12MAPK11 | |
| SCHEMBL5254805 | 0.75 | MAT2A (0.37) | MAPK14MAT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL1065956 | 0.75 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1065984 | 0.75 | MAPK14 (0.41) | MAPK14L3MBTL1MAPK13MAPK12MAPK11 | |
| SCHEMBL1065121 | 0.75 | MAPK14 (0.37) | MAPK14L3MBTL1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| US-7323472-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| EP-1333833-B1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases | GLAXOSMITHKLINE LLC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | US | disclosed |
| EP-1499320-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1499320-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
| WO-2003088972-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | MAPK8, MAPKAPK2, MAPK7 | MAPK14 14/4885MAT2A 2361/4885L3MBTL1 2566/4885 |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | MAPKAPK2, MAPK8, CREBBP | MAPK14 56/4885MAT2A 1859/4885L3MBTL1 2249/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | MAPK14 22/4885MAT2A 4057/4885L3MBTL1 2237/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAT2A 3628/4885L3MBTL1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.